Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409902 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5395750 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5395745 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5407136 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5409328 | 0.89 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5419467 | 0.89 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5409315 | 0.89 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4132380 | 0.82 | SLC6A4 (0.75) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4146202 | 0.82 | SLC6A4 (0.75) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4140535 | 0.82 | SLC6A4 (0.75) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199132-B2 | Tropane analogs and methods for inhibition of monoamine transport | ORGANIX, INC. (US) | 2007-04-03 | — | — | US | claimed |
| US-20030105125-A1 | Tropane analogs and methods for inhibition of monoamine transport | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-06-05 | — | — | US | claimed |
| US-20070244149-A1 | Tropane analogs and methods for inhibition of monoamine transport | ORGANIX, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7199132-B2 | Tropane analogs and methods for inhibition of monoamine transport | ORGANIX, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20030105125-A1 | Tropane analogs and methods for inhibition of monoamine transport | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105125-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | SLC6A4 2/4885SLC6A3 3/4885SLC6A2 1/4885 |
| US-20070244149-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | SLC6A4 2/4885SLC6A3 3/4885SLC6A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.